PLx Pharma Winddown Corp. Research and Development Expense (Excluding Acquired in Process Cost)
PLx Pharma Winddown Corp. reported Research and Development Expense (Excluding Acquired in Process Cost) of $14.69 thousand for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-04-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost · last filed 2017-04-17
- PLx Pharma Winddown Corp. research and development expense (excluding acquired in process cost) for the quarter ending 2017-03-31 was $14.69K, a 99.59% decline year-over-year.
- PLx Pharma Winddown Corp. research and development expense (excluding acquired in process cost) for the quarter ending 2016-12-31 was $2.36M, a 38.49% decline year-over-year.
- PLx Pharma Winddown Corp. research and development expense (excluding acquired in process cost) for the quarter ending 2016-09-30 was $3.11M, a 9.93% decline year-over-year.
- PLx Pharma Winddown Corp. research and development expense (excluding acquired in process cost) for the quarter ending 2016-06-30 was $3.70M, a 61.59% increase year-over-year.
- PLx Pharma Winddown Corp. research and development expense (excluding acquired in process cost) for fiscal 2016 was $12.75M, a 13.00% increase from fiscal 2015.
- PLx Pharma Winddown Corp. research and development expense (excluding acquired in process cost) for fiscal 2015 was $11.29M, a 26.84% increase from fiscal 2014.
- PLx Pharma Winddown Corp. research and development expense (excluding acquired in process cost) for fiscal 2014 was $8.90M, a 414.49% increase from fiscal 2013.
- PLx Pharma Winddown Corp. research and development expense (excluding acquired in process cost) for fiscal 2013 was $1.73M.
| Period end | Research and Development Expense (Excluding Acquired in Process Cost) 3 month | Research and Development Expense (Excluding Acquired in Process Cost) 6 month | Research and Development Expense (Excluding Acquired in Process Cost) 9 month | Research and Development Expense (Excluding Acquired in Process Cost) 12 month | Research and Development Expense (Excluding Acquired in Process Cost) 50 month |
|---|---|---|---|---|---|
| 2017-03-31 | $14.69K 10-Q · filed 2017-04-17 | $2.37M derived: sum of 2 quarters · filed 2017-04-17 | $5.48M derived: sum of 3 quarters · filed 2017-04-17 | $9.18M derived: sum of 4 quarters · filed 2017-04-17 | |
| 2016-12-31 | $2.36M derived: 10-K 12 month − 10-Q 9 month · filed 2017-01-20 | $5.47M derived: sum of 2 quarters · filed 2017-01-20 | $9.17M derived: sum of 3 quarters · filed 2017-01-20 | $12.75M 10-K · filed 2017-01-20 | |
| 2016-09-30 | $3.11M 10-Q · filed 2016-11-09 | $6.81M derived: sum of 2 quarters · filed 2016-11-09 | $10.40M 10-Q · filed 2016-11-09 | $14.23M derived: sum of 4 quarters · filed 2017-04-17 | |
| 2016-06-30 | $3.70M 10-Q · filed 2016-08-03 | $7.28M 10-Q · filed 2016-08-03 | $11.11M derived: sum of 3 quarters · filed 2017-04-17 | $14.57M derived: sum of 4 quarters · filed 2017-04-17 | |
| 2016-03-31 | $3.58M 10-Q · filed 2017-04-17 | $7.41M derived: sum of 2 quarters · filed 2017-04-17 | $10.87M derived: sum of 3 quarters · filed 2017-04-17 | $13.16M derived: sum of 4 quarters · filed 2017-04-17 | |
| 2015-12-31 | $3.83M derived: 10-K 12 month − 10-Q 9 month · filed 2017-01-20 | $7.29M derived: sum of 2 quarters · filed 2017-01-20 | $9.58M derived: sum of 3 quarters · filed 2017-01-20 | $11.29M 10-K · filed 2017-01-20 | |
| 2015-09-30 | $3.46M 10-Q · filed 2016-11-09 | $5.75M derived: sum of 2 quarters · filed 2016-11-09 | $7.46M 10-Q · filed 2016-11-09 | $9.42M derived: sum of 4 quarters · filed 2016-11-09 | |
| 2015-06-30 | $2.29M 10-Q · filed 2016-08-03 | $4.00M 10-Q · filed 2016-08-03 | $5.96M derived: sum of 3 quarters · filed 2016-08-03 | $8.49M derived: sum of 4 quarters · filed 2016-08-03 | |
| 2015-03-31 | $1.71M 10-Q · filed 2016-05-11 | $3.67M derived: sum of 2 quarters · filed 2016-05-11 | $6.20M derived: sum of 3 quarters · filed 2016-05-11 | $8.79M derived: sum of 4 quarters · filed 2016-05-11 | |
| 2014-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-22 | $4.49M derived: sum of 2 quarters · filed 2016-03-22 | $7.08M derived: sum of 3 quarters · filed 2016-03-22 | $8.90M 10-K · filed 2016-03-22 | |
| 2014-09-30 | $2.53M 10-Q · filed 2015-11-13 | $5.12M derived: sum of 2 quarters · filed 2015-11-13 | $6.94M 10-Q · filed 2015-11-13 | $7.88M derived: sum of 4 quarters · filed 2015-11-13 | |
| 2014-06-30 | $2.59M 10-Q · filed 2015-08-12 | $4.41M 10-Q · filed 2015-08-12 | $5.35M derived: sum of 3 quarters · filed 2015-08-12 | $5.98M derived: sum of 4 quarters · filed 2015-08-12 | |
| 2014-03-31 | $1.82M 10-Q · filed 2015-05-13 | $2.75M derived: sum of 2 quarters · filed 2015-05-13 | $3.39M derived: sum of 3 quarters · filed 2015-05-13 | $3.42M derived: sum of 4 quarters · filed 2015-05-13 | $5.64M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $936.76K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-23 | $1.57M derived: sum of 2 quarters · filed 2015-03-23 | $1.61M derived: sum of 3 quarters · filed 2015-03-23 | $1.73M 10-K · filed 2015-03-23 | |
| 2013-09-30 | $636.30K 10-Q · filed 2014-11-12 | $670.08K derived: sum of 2 quarters · filed 2014-11-12 | $792.78K 10-Q · filed 2014-11-12 | ||
| 2013-06-30 | $33.77K 10-Q · filed 2014-08-12 | $156.48K 10-Q · filed 2014-08-12 | |||
| 2013-03-31 | $122.70K 10-Q · filed 2014-05-12 |